Cargando…
Alemtuzumab in a Large Real-Life Cohort: Interim Baseline Data of the TREAT-MS Study
The non-interventional long-Term study foR obsErvAtion of Treatment with alemtuzumab in active relapsing–remitting MS (TREAT-MS) study collects the so far largest real-life cohort regarding utilization, long-term effectiveness, and safety of alemtuzumab, a humanized monoclonal antibody directed agai...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8375470/ https://www.ncbi.nlm.nih.gov/pubmed/34421780 http://dx.doi.org/10.3389/fneur.2021.620758 |
_version_ | 1783740320646692864 |
---|---|
author | Ziemssen, Tjalf Hoffmann, Frank Richter, Stephan Engelmann, Ulrich White, Robin |
author_facet | Ziemssen, Tjalf Hoffmann, Frank Richter, Stephan Engelmann, Ulrich White, Robin |
author_sort | Ziemssen, Tjalf |
collection | PubMed |
description | The non-interventional long-Term study foR obsErvAtion of Treatment with alemtuzumab in active relapsing–remitting MS (TREAT-MS) study collects the so far largest real-life cohort regarding utilization, long-term effectiveness, and safety of alemtuzumab, a humanized monoclonal antibody directed against the cell surface glycoprotein CD52, in adult patients with active relapsing–remitting multiple sclerosis (RRMS). An interim analysis of baseline parameters at inclusion of a non-interventional real-world study about alemtuzumab in Germany including previous multiple sclerosis (MS) medication utilization, MS activity, severity, and duration, as well as comorbidities was performed. Of the 883 patients, 71.6% were women. Mean age was 35.7 ± 9.2 years, time since first MS symptoms (=disease duration) is 8.0 ± 6.8 years, and Expanded Disability Status Scale (EDSS) is 2.7 ± 1.8 points (range, 0.0–7.5 points). The number of relapses in the 12 and 24 months prior to inclusion were 1.6 ± 1.2 and 2.2 ± 1.8, respectively. Of the patients, 14.4% were treatment naive, while for the majority, a wide spectrum of MS disease-modifying treatments (DMTs) and treatment sequences were documented. Overall, interferon beta (IFN-beta) was reported most frequently (52.4%), followed by fingolimod (35.2%), natalizumab (34.9%), and glatiramer acetate (28.9%). Patients with longer disease duration and higher EDSS had a higher number of previous DMTs. Compared to the pivotal phase 2/3 studies, RRMS patients starting alemtuzumab treatment had a longer disease duration in real-world conditions. There was variety of different treatment sequences before the final switch to alemtuzumab. In the future, linking these treatment sequences or other baseline characteristics with effectiveness and safety outcomes might be useful to support treatment decisions. Registered at Paul-Ehrlich-Institut under NIS 281. |
format | Online Article Text |
id | pubmed-8375470 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-83754702021-08-20 Alemtuzumab in a Large Real-Life Cohort: Interim Baseline Data of the TREAT-MS Study Ziemssen, Tjalf Hoffmann, Frank Richter, Stephan Engelmann, Ulrich White, Robin Front Neurol Neurology The non-interventional long-Term study foR obsErvAtion of Treatment with alemtuzumab in active relapsing–remitting MS (TREAT-MS) study collects the so far largest real-life cohort regarding utilization, long-term effectiveness, and safety of alemtuzumab, a humanized monoclonal antibody directed against the cell surface glycoprotein CD52, in adult patients with active relapsing–remitting multiple sclerosis (RRMS). An interim analysis of baseline parameters at inclusion of a non-interventional real-world study about alemtuzumab in Germany including previous multiple sclerosis (MS) medication utilization, MS activity, severity, and duration, as well as comorbidities was performed. Of the 883 patients, 71.6% were women. Mean age was 35.7 ± 9.2 years, time since first MS symptoms (=disease duration) is 8.0 ± 6.8 years, and Expanded Disability Status Scale (EDSS) is 2.7 ± 1.8 points (range, 0.0–7.5 points). The number of relapses in the 12 and 24 months prior to inclusion were 1.6 ± 1.2 and 2.2 ± 1.8, respectively. Of the patients, 14.4% were treatment naive, while for the majority, a wide spectrum of MS disease-modifying treatments (DMTs) and treatment sequences were documented. Overall, interferon beta (IFN-beta) was reported most frequently (52.4%), followed by fingolimod (35.2%), natalizumab (34.9%), and glatiramer acetate (28.9%). Patients with longer disease duration and higher EDSS had a higher number of previous DMTs. Compared to the pivotal phase 2/3 studies, RRMS patients starting alemtuzumab treatment had a longer disease duration in real-world conditions. There was variety of different treatment sequences before the final switch to alemtuzumab. In the future, linking these treatment sequences or other baseline characteristics with effectiveness and safety outcomes might be useful to support treatment decisions. Registered at Paul-Ehrlich-Institut under NIS 281. Frontiers Media S.A. 2021-08-05 /pmc/articles/PMC8375470/ /pubmed/34421780 http://dx.doi.org/10.3389/fneur.2021.620758 Text en Copyright © 2021 Ziemssen, Hoffmann, Richter, Engelmann and White. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Neurology Ziemssen, Tjalf Hoffmann, Frank Richter, Stephan Engelmann, Ulrich White, Robin Alemtuzumab in a Large Real-Life Cohort: Interim Baseline Data of the TREAT-MS Study |
title | Alemtuzumab in a Large Real-Life Cohort: Interim Baseline Data of the TREAT-MS Study |
title_full | Alemtuzumab in a Large Real-Life Cohort: Interim Baseline Data of the TREAT-MS Study |
title_fullStr | Alemtuzumab in a Large Real-Life Cohort: Interim Baseline Data of the TREAT-MS Study |
title_full_unstemmed | Alemtuzumab in a Large Real-Life Cohort: Interim Baseline Data of the TREAT-MS Study |
title_short | Alemtuzumab in a Large Real-Life Cohort: Interim Baseline Data of the TREAT-MS Study |
title_sort | alemtuzumab in a large real-life cohort: interim baseline data of the treat-ms study |
topic | Neurology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8375470/ https://www.ncbi.nlm.nih.gov/pubmed/34421780 http://dx.doi.org/10.3389/fneur.2021.620758 |
work_keys_str_mv | AT ziemssentjalf alemtuzumabinalargereallifecohortinterimbaselinedataofthetreatmsstudy AT hoffmannfrank alemtuzumabinalargereallifecohortinterimbaselinedataofthetreatmsstudy AT richterstephan alemtuzumabinalargereallifecohortinterimbaselinedataofthetreatmsstudy AT engelmannulrich alemtuzumabinalargereallifecohortinterimbaselinedataofthetreatmsstudy AT whiterobin alemtuzumabinalargereallifecohortinterimbaselinedataofthetreatmsstudy |